Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder, Major | 29 | 2022 | 108 | 4.980 |
Why?
|
| Antidepressive Agents | 26 | 2023 | 100 | 3.420 |
Why?
|
| Depressive Disorder | 30 | 2007 | 192 | 2.880 |
Why?
|
| Bipolar Disorder | 14 | 2017 | 130 | 2.160 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 6 | 2023 | 9 | 2.020 |
Why?
|
| Antidepressive Agents, Second-Generation | 13 | 2010 | 28 | 1.370 |
Why?
|
| Psychiatric Status Rating Scales | 26 | 2020 | 356 | 1.150 |
Why?
|
| Ketamine | 2 | 2023 | 35 | 0.980 |
Why?
|
| Fluoxetine | 15 | 2009 | 33 | 0.960 |
Why?
|
| Antipsychotic Agents | 9 | 2016 | 68 | 0.960 |
Why?
|
| Secondary Prevention | 16 | 2020 | 67 | 0.870 |
Why?
|
| Triazoles | 7 | 2003 | 34 | 0.850 |
Why?
|
| Double-Blind Method | 29 | 2020 | 499 | 0.840 |
Why?
|
| Vagus Nerve Stimulation | 2 | 2022 | 8 | 0.770 |
Why?
|
| Tetrahydrofolates | 3 | 2016 | 3 | 0.770 |
Why?
|
| Valproic Acid | 5 | 2008 | 30 | 0.740 |
Why?
|
| Substance Withdrawal Syndrome | 6 | 2003 | 36 | 0.720 |
Why?
|
| Treatment Outcome | 34 | 2022 | 3806 | 0.700 |
Why?
|
| Depression | 7 | 2022 | 481 | 0.700 |
Why?
|
| Humans | 78 | 2023 | 30994 | 0.640 |
Why?
|
| Cyclohexanols | 9 | 2010 | 18 | 0.640 |
Why?
|
| Drug Therapy, Combination | 15 | 2019 | 246 | 0.610 |
Why?
|
| Suicidal Ideation | 1 | 2017 | 5 | 0.570 |
Why?
|
| Adult | 45 | 2019 | 8929 | 0.570 |
Why?
|
| Sexual Dysfunctions, Psychological | 5 | 2005 | 11 | 0.570 |
Why?
|
| Male | 56 | 2020 | 16442 | 0.540 |
Why?
|
| Female | 54 | 2020 | 16980 | 0.510 |
Why?
|
| Piperazines | 11 | 2015 | 91 | 0.500 |
Why?
|
| Middle Aged | 36 | 2020 | 10192 | 0.490 |
Why?
|
| Electroconvulsive Therapy | 3 | 2017 | 17 | 0.470 |
Why?
|
| Folic Acid | 2 | 2016 | 16 | 0.420 |
Why?
|
| Anxiety Disorders | 4 | 2002 | 171 | 0.400 |
Why?
|
| Drug Administration Schedule | 15 | 2007 | 225 | 0.380 |
Why?
|
| Acetamides | 1 | 2010 | 7 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2020 | 442 | 0.340 |
Why?
|
| Sexual Behavior | 2 | 2002 | 60 | 0.340 |
Why?
|
| Pirenzepine | 3 | 2003 | 5 | 0.320 |
Why?
|
| Adolescent | 13 | 2015 | 2401 | 0.300 |
Why?
|
| Personality Inventory | 5 | 2012 | 75 | 0.280 |
Why?
|
| Acute Disease | 7 | 2013 | 231 | 0.280 |
Why?
|
| Antimanic Agents | 1 | 2006 | 10 | 0.280 |
Why?
|
| Social Adjustment | 2 | 2010 | 31 | 0.260 |
Why?
|
| Administration, Intranasal | 2 | 2023 | 26 | 0.260 |
Why?
|
| Sertraline | 5 | 2006 | 23 | 0.250 |
Why?
|
| Aged | 17 | 2016 | 10045 | 0.240 |
Why?
|
| Remission Induction | 5 | 2020 | 105 | 0.230 |
Why?
|
| Chronic Disease | 6 | 2017 | 532 | 0.230 |
Why?
|
| Surveys and Questionnaires | 5 | 2015 | 1210 | 0.230 |
Why?
|
| Venlafaxine Hydrochloride | 9 | 2010 | 17 | 0.230 |
Why?
|
| Obsessive-Compulsive Disorder | 4 | 2006 | 23 | 0.230 |
Why?
|
| Placebos | 7 | 2006 | 79 | 0.220 |
Why?
|
| Prospective Studies | 4 | 2017 | 1898 | 0.220 |
Why?
|
| Obesity | 3 | 2015 | 307 | 0.220 |
Why?
|
| Recurrence | 5 | 2016 | 370 | 0.210 |
Why?
|
| Ambulatory Care | 7 | 2008 | 79 | 0.200 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 1921 | 0.190 |
Why?
|
| Young Adult | 5 | 2016 | 2063 | 0.190 |
Why?
|
| Combined Modality Therapy | 6 | 2020 | 386 | 0.180 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2020 | 3 | 0.180 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 13 | 0.170 |
Why?
|
| Pyrrolidines | 1 | 2020 | 21 | 0.170 |
Why?
|
| Benzamides | 1 | 2020 | 21 | 0.170 |
Why?
|
| Quality of Life | 5 | 2010 | 697 | 0.170 |
Why?
|
| Patient Compliance | 5 | 2007 | 158 | 0.160 |
Why?
|
| Psychotic Disorders | 2 | 2001 | 47 | 0.150 |
Why?
|
| Long-Term Care | 2 | 2016 | 57 | 0.150 |
Why?
|
| Thiazoles | 2 | 2012 | 31 | 0.150 |
Why?
|
| Antidepressive Agents, Tricyclic | 3 | 2004 | 22 | 0.150 |
Why?
|
| C-Reactive Protein | 2 | 2015 | 128 | 0.140 |
Why?
|
| Severity of Illness Index | 6 | 2007 | 1133 | 0.140 |
Why?
|
| Phenethylamines | 1 | 2016 | 4 | 0.140 |
Why?
|
| Pyridines | 1 | 2016 | 47 | 0.140 |
Why?
|
| Comorbidity | 6 | 2015 | 507 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 360 | 0.130 |
Why?
|
| Glutamates | 1 | 2015 | 17 | 0.130 |
Why?
|
| Registries | 1 | 2017 | 201 | 0.130 |
Why?
|
| Serotonin | 2 | 1997 | 37 | 0.130 |
Why?
|
| Psychometrics | 5 | 2012 | 270 | 0.130 |
Why?
|
| Dizziness | 4 | 2007 | 20 | 0.130 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2007 | 5 | 0.130 |
Why?
|
| Hypericum | 2 | 2005 | 3 | 0.130 |
Why?
|
| Paroxetine | 4 | 2007 | 14 | 0.120 |
Why?
|
| Phytotherapy | 2 | 2005 | 14 | 0.120 |
Why?
|
| Sulfides | 1 | 2015 | 12 | 0.120 |
Why?
|
| Anti-Anxiety Agents | 1 | 2015 | 40 | 0.120 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2014 | 1 | 0.120 |
Why?
|
| Aldehydes | 1 | 2014 | 2 | 0.120 |
Why?
|
| S-Adenosylmethionine | 1 | 2014 | 6 | 0.120 |
Why?
|
| Administration, Oral | 2 | 2019 | 139 | 0.120 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2000 | 61 | 0.110 |
Why?
|
| Vagus Nerve | 2 | 2022 | 16 | 0.110 |
Why?
|
| Nausea | 3 | 1999 | 27 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 407 | 0.110 |
Why?
|
| Inflammation | 1 | 2015 | 362 | 0.110 |
Why?
|
| Anticonvulsants | 2 | 2003 | 112 | 0.100 |
Why?
|
| Tranylcypromine | 1 | 1991 | 2 | 0.100 |
Why?
|
| Hypertension | 2 | 2007 | 288 | 0.100 |
Why?
|
| Prevalence | 1 | 2013 | 499 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 75 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2005 | 818 | 0.090 |
Why?
|
| Headache | 3 | 2007 | 43 | 0.090 |
Why?
|
| Orgasm | 1 | 1991 | 9 | 0.090 |
Why?
|
| Patient Education as Topic | 3 | 2003 | 161 | 0.090 |
Why?
|
| Fever | 1 | 1991 | 42 | 0.090 |
Why?
|
| Attitude to Health | 2 | 2002 | 100 | 0.090 |
Why?
|
| Rhabdomyolysis | 1 | 2010 | 5 | 0.090 |
Why?
|
| Duloxetine Hydrochloride | 2 | 2015 | 10 | 0.090 |
Why?
|
| Choice Behavior | 1 | 2010 | 56 | 0.090 |
Why?
|
| Electroencephalography | 1 | 2010 | 136 | 0.080 |
Why?
|
| Patient Selection | 1 | 2011 | 246 | 0.080 |
Why?
|
| Tachyphylaxis | 1 | 2009 | 1 | 0.080 |
Why?
|
| Delayed-Action Preparations | 4 | 2010 | 33 | 0.080 |
Why?
|
| Benzodiazepines | 3 | 2003 | 58 | 0.080 |
Why?
|
| Sleep Stages | 2 | 1999 | 34 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2015 | 1055 | 0.070 |
Why?
|
| 1-Naphthylamine | 2 | 1997 | 4 | 0.070 |
Why?
|
| Ribavirin | 1 | 2007 | 32 | 0.070 |
Why?
|
| Half-Life | 2 | 1997 | 15 | 0.070 |
Why?
|
| Serotonin Antagonists | 2 | 2001 | 14 | 0.070 |
Why?
|
| Syndrome | 2 | 1997 | 83 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2007 | 68 | 0.070 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2004 | 8 | 0.070 |
Why?
|
| Analysis of Variance | 4 | 2010 | 324 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 80 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2007 | 135 | 0.060 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 93 | 0.060 |
Why?
|
| Weight Gain | 3 | 2001 | 70 | 0.060 |
Why?
|
| Electric Stimulation Therapy | 1 | 2005 | 46 | 0.060 |
Why?
|
| Sex Factors | 2 | 2005 | 511 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2007 | 3656 | 0.060 |
Why?
|
| Thiophenes | 1 | 2004 | 13 | 0.060 |
Why?
|
| Psychotherapy | 1 | 2003 | 35 | 0.050 |
Why?
|
| Morpholines | 1 | 2003 | 15 | 0.050 |
Why?
|
| Health Status | 3 | 2003 | 239 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2002 | 11 | 0.050 |
Why?
|
| Body Weight | 2 | 2002 | 141 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2003 | 58 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2002 | 49 | 0.050 |
Why?
|
| Biomarkers | 2 | 2015 | 733 | 0.050 |
Why?
|
| Drug Interactions | 2 | 1991 | 61 | 0.050 |
Why?
|
| Mianserin | 1 | 2001 | 15 | 0.050 |
Why?
|
| Buspirone | 1 | 2001 | 6 | 0.050 |
Why?
|
| Bupropion | 1 | 2001 | 6 | 0.050 |
Why?
|
| Sildenafil Citrate | 1 | 2001 | 10 | 0.050 |
Why?
|
| Psychomotor Agitation | 1 | 2001 | 14 | 0.050 |
Why?
|
| Sulfones | 1 | 2001 | 25 | 0.050 |
Why?
|
| Sexuality | 1 | 2001 | 16 | 0.050 |
Why?
|
| Telephone | 1 | 2000 | 26 | 0.050 |
Why?
|
| Central Nervous System Stimulants | 1 | 2001 | 53 | 0.040 |
Why?
|
| Purines | 1 | 2001 | 34 | 0.040 |
Why?
|
| Self Disclosure | 1 | 2000 | 6 | 0.040 |
Why?
|
| Asthenia | 1 | 2000 | 1 | 0.040 |
Why?
|
| Desipramine | 1 | 2000 | 6 | 0.040 |
Why?
|
| Feeding and Eating Disorders | 1 | 2000 | 12 | 0.040 |
Why?
|
| Nasal Sprays | 1 | 2019 | 3 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2000 | 79 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2002 | 344 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 582 | 0.040 |
Why?
|
| Drug Synergism | 2 | 1995 | 66 | 0.040 |
Why?
|
| Anxiety | 1 | 1999 | 156 | 0.040 |
Why?
|
| Fluvoxamine | 1 | 1997 | 2 | 0.040 |
Why?
|
| MEDLINE | 1 | 1997 | 5 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 1997 | 13 | 0.040 |
Why?
|
| Prognosis | 1 | 2000 | 918 | 0.040 |
Why?
|
| Abbreviations as Topic | 1 | 1997 | 1 | 0.040 |
Why?
|
| Paresthesia | 1 | 1997 | 6 | 0.040 |
Why?
|
| Receptors, Serotonin | 1 | 1997 | 18 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 1997 | 12 | 0.040 |
Why?
|
| Norepinephrine | 1 | 1997 | 21 | 0.040 |
Why?
|
| Neurotransmitter Agents | 1 | 1997 | 19 | 0.040 |
Why?
|
| Medical Records | 1 | 1997 | 34 | 0.030 |
Why?
|
| Life Change Events | 1 | 1997 | 38 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1997 | 25 | 0.030 |
Why?
|
| Quetiapine Fumarate | 1 | 2016 | 2 | 0.030 |
Why?
|
| Time Factors | 3 | 2010 | 1672 | 0.030 |
Why?
|
| Down-Regulation | 1 | 1997 | 113 | 0.030 |
Why?
|
| Triazines | 1 | 2016 | 17 | 0.030 |
Why?
|
| Imipramine | 1 | 1996 | 12 | 0.030 |
Why?
|
| Community Mental Health Services | 1 | 1996 | 12 | 0.030 |
Why?
|
| Family Practice | 1 | 1996 | 20 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2006 | 60 | 0.030 |
Why?
|
| Adiponectin | 1 | 2015 | 9 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 1995 | 11 | 0.030 |
Why?
|
| Leptin | 1 | 2015 | 24 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 1997 | 330 | 0.030 |
Why?
|
| Primary Health Care | 1 | 1997 | 100 | 0.030 |
Why?
|
| Mental Disorders | 1 | 1997 | 145 | 0.030 |
Why?
|
| Infant | 1 | 1997 | 578 | 0.030 |
Why?
|
| Plant Extracts | 2 | 2005 | 17 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 1997 | 637 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 112 | 0.030 |
Why?
|
| Affect | 1 | 1995 | 66 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1995 | 44 | 0.030 |
Why?
|
| Phobic Disorders | 1 | 1995 | 66 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 234 | 0.030 |
Why?
|
| Incidence | 1 | 1997 | 785 | 0.030 |
Why?
|
| Panic Disorder | 1 | 1995 | 131 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 1995 | 84 | 0.030 |
Why?
|
| Carbamazepine | 1 | 1993 | 13 | 0.030 |
Why?
|
| Lithium | 1 | 1993 | 22 | 0.030 |
Why?
|
| Genotype | 1 | 2014 | 429 | 0.030 |
Why?
|
| Child | 1 | 1997 | 1429 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 99 | 0.030 |
Why?
|
| Amitriptyline | 1 | 1991 | 4 | 0.020 |
Why?
|
| Sympathomimetics | 1 | 1991 | 8 | 0.020 |
Why?
|
| Pemoline | 1 | 1991 | 2 | 0.020 |
Why?
|
| Dextroamphetamine | 1 | 1991 | 5 | 0.020 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1991 | 20 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 1991 | 28 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 1316 | 0.020 |
Why?
|
| Drugs, Investigational | 1 | 1990 | 9 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 120 | 0.020 |
Why?
|
| Risk Factors | 1 | 1997 | 2586 | 0.020 |
Why?
|
| Hospitalization | 1 | 1991 | 336 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 190 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2007 | 54 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2007 | 24 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 46 | 0.020 |
Why?
|
| Outpatients | 1 | 2007 | 57 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 147 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1504 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2005 | 28 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2005 | 32 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 229 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2007 | 254 | 0.010 |
Why?
|
| Eligibility Determination | 1 | 2003 | 5 | 0.010 |
Why?
|
| United States | 1 | 2010 | 2375 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2003 | 72 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 662 | 0.010 |
Why?
|
| Health Services | 1 | 2003 | 9 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2003 | 320 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2003 | 71 | 0.010 |
Why?
|
| Priapism | 1 | 2002 | 10 | 0.010 |
Why?
|
| Suicide | 1 | 2002 | 14 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2001 | 28 | 0.010 |
Why?
|
| Seizures | 1 | 2002 | 94 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2001 | 12 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2001 | 70 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 2001 | 26 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2001 | 167 | 0.010 |
Why?
|
| Schizophrenia | 1 | 2001 | 82 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 310 | 0.010 |
Why?
|
| Appetite | 1 | 1999 | 5 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 873 | 0.010 |
Why?
|
| Weight Loss | 1 | 1999 | 117 | 0.010 |
Why?
|
| Body Mass Index | 1 | 1999 | 452 | 0.010 |
Why?
|